BioCentury
ARTICLE | Company News

Management tracks: Portola, Assembly, Entasis

April 24, 2019 11:12 PM UTC

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective May 1, while Curnutte will remain in a consultancy role.

Portola also said VP of Medical Affairs Jeff Myers will serve as interim CMO until it completes its previously announced search for a successor to John Lawrence, who stepped down in January. ...